Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

Ozempic, a once weekly injectable GLP-1 agonist drug, is now approved to reduce the risk of heart attack and stroke. Rybelsus (a pill version of Ozempic) is confirmed to...
Read on to learn about the research around GLP-1, SGLT-2, and combination therapy use in type 1 diabetes. Dr. Paresh Dandona is a Distinguished Professor and Chief of...
New guidelines from ADA and EASD focus on GLP-1 agonists and SGLT-2 inhibitors to improve heart and kidney health
Farxiga’s heart health benefits were the same in people with and without diabetes, as well as across a spectrum of baseline A1C levels
Control-IQ the first AID system with automatic correction boluses and no fingersticks CGM (Dexcom G6); cleared for those ages 14 and older; launch in January 2020
A new paper suggests that as people with diabetes increase their time in range, healthcare costs decrease
As we demand more nutritious and sustainable food, big food companies must make adjustments to their products, practices, and marketing
Will the medication move from “off label” to standard of care for people at high risk of developing type 2 diabetes?
By Ursula Biba and Eliza Skoler The new State of Childhood Obesity report and website show that youth obesity is prevalent in the US, leading to high rates of adult...
The diaTribe team was in Barcelona for the 55 th Annual Meeting of the European Association for the Study of Diabetes. Check out our biggest highlights from the...
A collaboration between JDRF, Stanford, and UCSF aims to cure type 1 diabetes through understanding of stem cells and the immune system
Are people aware of the link between diabetes and heart health? Do they know that certain diabetes drugs may protect the heart? Is heart health commonly discussed with...
For now, another SGLT-2 inhibitor pill already approved for people with type 2 diabetes is not approved for people with type 1 diabetes in the US. The drug was recently...
Virta’s program resulted in “reversal” of type 2 diabetes in 54% of participants after two years. Data show 10% bodyweight loss, 0.9% A1C reduction, and reduced need for...
The first GLP-1 pill for type 2 diabetes offers weight loss and A1C reduction without injections; US decision expected in September 2019, EU decision expected spring of...
Big focus on heart health outcome trials with PIONEER 6 and CAROLINA in the spotlight; plus promising CGM data in adolescents with type 1 diabetes
The EMA approved Zynquista (sotagliflozin), an SGLT-1/2 dual inhibitor, for adults with a BMI above 27
Results from the CREDENCE trial suggest that Invokana’s kidney benefits exist on top of blood pressure lowering medications (standard of care)
A huge milestone that makes Forxiga the first pill for people with type 1 diabetes in Europe
Zynquista was not approved by the FDA; Complete Response Letter suggests the FDA is weighing safety concerns of the SGLT-1/2 dual inhibitor for type 1 diabetes

Pages